par Felip, Enriqueta;Smit, Egbert F;Molina-Vila, Miguel A;Dafni, Urania;Massuti, Bartomeu;Berghmans, Thierry 
;de Marinis, Filippo;Passiglia, Francesco;Dingemans, Anne-Marie C;Cobo, Manuel;Viteri, Santiago;Britschgi, Christian;Cuffe, Sinead;Provencio, Mariano;Merkelbach-Bruse, Sabine;Andriakopoulou, Charitini;Kammler, Roswitha;Ruepp, Barbara;Roschitzki-Voser, Heidi;Peters, Solange;Wolf, Jürgen;Stahel, Rolf Arno R.;ETOP 12-17 ALERT-lung Collaborators,
Référence Lung cancer, 172, page (94-99)
Publication Publié, 2022-08
;de Marinis, Filippo;Passiglia, Francesco;Dingemans, Anne-Marie C;Cobo, Manuel;Viteri, Santiago;Britschgi, Christian;Cuffe, Sinead;Provencio, Mariano;Merkelbach-Bruse, Sabine;Andriakopoulou, Charitini;Kammler, Roswitha;Ruepp, Barbara;Roschitzki-Voser, Heidi;Peters, Solange;Wolf, Jürgen;Stahel, Rolf Arno R.;ETOP 12-17 ALERT-lung Collaborators, Référence Lung cancer, 172, page (94-99)
Publication Publié, 2022-08
Article révisé par les pairs
| Résumé : | Alectinib, a highly selective next generation ALK-inhibitor, has exhibited potent anti-tumour activity in RET-rearranged NSCLC in the preclinical stage. |
